Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The case of acute alcoholic pancreatitis, complicated by internal pancreatic fistula is being reported. The general patients symptom in initial illness period was ascites in peritoneal cavity. Biochemical investigation of ascites has shown elevated activity of amylase and protein which is typical for pancreatic ascites. The late diagnosis of ascites cause (in 3rd week of the illness) and complications decreased efficacy of the treatment used (parenteral nutrition and somatostatin). Thus worse the course of the illness.
Pol Arch Med Wewn 1997 Jan
PMID:[A case of ascites in the course of acute pancreatitis]. 923 53

The authors present clinical features, diagnostic approach and treatment of inappropriate TSH secretion syndrome. To data above 80 cases of this syndrome have been described. The main clinical features are thyrotoxicosis and vascular goiter present in the patient with pituitary adenoma. High concentrations of free thyroid hormones coexist with elevated TSH serum level. In some cases hyperproduction of other anterior lobe pituitary hormones was found. The molar ratio alpha subunit to TSH exceeds 1.0. In the management of inappropriate TSH secretion syndrome hypophysectomy, irradiation and long-acting somatostatin analog octreotide are applied.
Pol Merkur Lekarski 1998 Aug
PMID:[The syndrome of inappropriate TSH secretion of neoplastic origin (NIST)]. 1010 68

Immunostaining for chromogranin A, serotonin, glucagon and somatostatin revealed the presence of endocrine cells in 20 (35.1%) out of 57 randomly selected colorectal carcinomas. Expression of a general "neuroendocrine" marker, chromogranin A was detected in 18 tumours, whereas in the remaining two carcinomas positive reactivity with glucagon only was seen. Serotonin was expressed in 9 carcinomas, glucagon in 5 and somatostatin in 4 carcinomas. In 3 tumours coexpression of active products was found: in one--serotonin and glucagon, in another--serotonin and somatostatin, and in the last one--serotonin, glucagon and somatostatin. In 6 carcinomas expressing chromogranin A there was no expression of active products. Twelve carcinomas were assigned to a group with a small number of endocrine cells (up to 50/cm2 of tumour cross sectional area), 6 to a group with an intermediate number of endocrine cells (over 50 to 500/cm2) and 2 to a group with a large number of endocrine cells (over 500/cm2). The endocrine cells were significantly more frequent in less advanced and better differentiated carcinomas and in neoplasms with abundant mucin production. The cells were an integral part of glandular structures of the carcinoma, which argues in favour of a unitarian theory, i.e. common, endodermal origin of endocrine cells and other cellular elements of intestinal epithelium.
Pol J Pathol 2000
PMID:Endocrine cells in colorectal carcinomas. Immunohistochemical study. 1124 95

To evaluate the therapeutic efficacy of slow releasing analogue of somatostatin (SR-Lanreotide) in the pretreatment for GH-releasing adenomas, especially macroadenomas. During the last four years (between January 1996 and December 1999) the authors carried out 382 transsphenoidal operations for to various lesions. There were 169 acromegalic patients in this group. 82 of them received, as pretreatment, the slow releasing analogue of somatostatin (SR-Lanreotide, BIM 23014) in a dose of 30 mg every 14 days for 3 months (6 injections). There were 55 women and 27 men (range 25-68, mean age 44.8 years, SD +/- 10 years) operated on by one experienced neurosurgeon. The concentrations of serum GH--70.5 micrograms/l (range 5.3-500 micrograms/l, SD +/- 83.9 micrograms/l) and IGF-I--1302 micrograms/l (range 610-2030 micrograms/l, SD +/- 360.7 micrograms/l) were high. Out of these 82 patients 79 had macroadenomas with suprasellar and parasellar extension. The volume of the tumours was calculated according to the formula of Di Chiro-Nelson. The mean volume of the tumour was 4146.9 mm3 (range 213.5-38595.3 mm3, SD +/- 5675.9 mm3). The response to the pretreatment suppression of the serum GH, IGF-I level and shrinkage of the tumours--were evaluated before surgery. Second MR examination was performed in 38 pretreated patients. During the Lanreotide treatment mean serum GH level decreased from 70.5 to 15.6 micrograms/l (p < 0.0001), mean serum IGF-I concentration decreased from 1302 to 787 micrograms/l and mean volume of the tumour decreased from 5662 to 2326 mm3 (p < 0.0001). During surgery, tumours were observed to be softer, had liquid consistency and were easier removed. 57 patient (69.5%) who underwent surgery had GH below 5 micrograms/l and were cured. Transsphenoidal microsurgical resection of pituitary adenomas is the primary treatment for acromegaly. Lanreotide pretreatment significantly decreased mean serum GH and IGF-I level, shrinks the tumour and make it much softer and easier to be removed.
Neurol Neurochir Pol
PMID:[Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma]. 1173 66

Acromegaly is caused by excessive secretion of growth hormone by a hypophyseal adenoma type of somatotropinoma. IGF-I is formed in the liver and mediates most biological actions of GH. Treatment of adenomas, which secrete GH, involves pharmacotherapy followed by surgery. Modern pharmacotherapy leaning is based on somatostatin analogues (factor restrictive secretion GH): octreotide, octreotide LAR and lanreotide. The aim of our study was estimation of efficiency of octreotide LAR in the patients with somatotropinoma prepared to neurosurgery intervention. We examined 16 patients (10 of women and 6 men) with the features of active acromegaly. In all cases the increased concentration of HGH and IGF-I were observed. The presence of pituitary adenoma in all patients was confirmed by MRI. The patients were treated with octreotide LAR monthly in dose 20 mg and 30 mg respectively. Before and after application of somatostatin analogues the concentration HGH, IGF-I, PRL in serum were marked. The concentration of GH before octreotide LAR therapy in all patients increased remarkable and ranged from 15.6 to 78.6 ng/ml, mean: 31.20 +/- 16.84 (norm: 0-10 ng/ml), also, in all cases the serum IGF-I level was increased and ranged from 451 to 1107.6 ng/ml, mean: 801.75 +/- 207.82 (norm: 100-400 ng/ml). The prolactin concentration ranged from 7.4 to 49.9 ng/ml, mean: 22.8 +/- 13.7 (norm: 2-20 ng/ml) and in 8 (50%) cases the increased of PRL concentration in serum was observed. After the administration of octreotide LAR the level of: GH [mean: 12.99 +/- 17.16 ng/ml (p < 0.001)], of IGF-I [mean 422.8 +/- 229 ng ml (p < 0.01)] statistical important decreased and prolactin in 8 with increased concentration [mean: 12.45 +/- 5.57 (p < 0.01)] were observed. Long acting somatostatin analogues--octreotide LAR is particular efficient in lowering of growth hormone and IGF-I in patients with somatotropinoma and shows efficiency in normalization of increased prolactin concentration. Because of extreme effectiveness of octreotide LAR, it should be used the routine treatment at the patients suffering from active acromegaly and preparing to neurosurgical treatment.
Pol Arch Med Wewn 2001 Aug
PMID:[Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma]. 1192 44

The presence of choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAChT), neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP), somatostatin (SOM), galanin (GAL), substance P (SP) and calcitonin gene-related peptide (CGRP) was studied in neurons and nerve fibers of the porcine otic ganglion. ChAT-positive neurons were very numerous while VAChT-positive nerve cells were moderate in number. The number of neurons containing NPY and VIP was lower and those containing SOM, GAL, SP or CGRP were observed as scarce, or single nerve cells. The above mentioned substances (except SOM) were present in nerve fibers of the ganglion. ChAT- and VAChT-positive nerve fibers were numerous, while the number of nerve terminals containing NPY, VIP and SP was lower. GAL- and CGRP-positive nerve fibers were scarce.
Pol J Vet Sci 2002
PMID:Immunohistochemical study of the otic ganglion in the pig. 1251 60

The expression of neuropeptide Y (NPY), galanin (GAL), vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), somatostatin (SOM) and substance P (SP) was studied in the neurons of the inferior mesenteric ganglion (IMG) projecting to the uterine horn and uterine cervix after uterus extirpation-induced axotomy in sexually immature gilts. The expression was studied with immunohistochemistry, in situ hybridization and RT-PCR. Uterus-projecting neurons were identified by retrograde tracing with Fast Blue (FB). Immunohistochemistry revealed that FB-positive (FB+) uterus-projecting neurons in control animals contained only immunoreactivities to NPY (ca. 50%) and GAL (single neurons). Uterus extirpation increased the occurrence of NPY and GAL in FB+ neurons. No other studied neuropeptides were found in axotomized uterus-projecting neurons. Hybridization in situ revealed the reduction of NPY expression and induction of GAL expression in FB+ neurons. RT-PCR detected induction of GAL expression in the IMG after uterus extirpation. The expression level of NPY and SOM was significant and was not affected by axotomy. The expression level of PACAP was very low and did not differ between IMG of control, partially and totally hysterectomized animals. No VIP and SP expression was detected in all ganglia. The presented data show clear axotomy-related changes in the expression of GAL and NPY in the uterus-projecting neurons of the porcine IMG.
Pol J Vet Sci 2003
PMID:Effect of total or partial uterus extirpation on sympathetic uterus-projecting neurons in porcine inferior mesenteric ganglion. B. Changes in expression of neuropeptide Y, galanin, vasoactive intestinal polypeptide, pituitary adenylate-cyclase activating peptide, somatostatin and substance P. 1281 85

The affinity of various malignant neoplasms including small cell and non-small cell lung cancer for peptide analogue of somatostatin has been documented. Depreotide is such an analogue and can be combined with technetium--99m (99mTc depreotide) for optical imaging properties. Using this radiopharmaceutical product, solitary pulmonary nodules (SPN) were previously successful evaluated. In this article the preliminary study of the depreotide (NeoSpect--Amersham, Wielka Brytania) in clinical practice has been shown.
Pol Merkur Lekarski 2003 Mar
PMID:[The advantages of depreotide in the diagnosis of spherical solitary pulmonary nodules (SPN): preliminary study]. 1291 90

We report the case of 48-year old patient with carcinoid syndrome successfully treated with somatostatin analogues. We also present the review of published literature about the use of somatostatin analogues in the treatment of carcinoid syndrome. In addition, reported case shows difficulties in access to this treatment, caused by economical reasons.
Pol Arch Med Wewn 2003 Sep
PMID:[Somatostatin analogs in the treatment of carcinoid syndrome: a case report and review of literature]. 1469 93

In the male pig, the bulbourethral gland (BG) is a particulary well developed accessory genital gland (AGG) which produces complex secretion contributing to the fluid component of semen. The secretory and motor function of AGGs is thought to be under the autonomic nervous system control. Although relatively much is known about the innervation of the prostate gland and, to a lesser degree, of the seminal vesicle, the paucity of data dealing with the innervation of BG is striking. Therefore, combined retrograde tracing and double-labelling immunofluorescence have been used to investigate the distribution and immunohistochemical properties of autonomic and primary afferent neurons projecting to this gland in the pig. BG-projecting neurons were found in some ipsilateral (I) and contralateral (C) sympathetic chain ganglia (SChG), the caudal mesenteric ganglion (CaMG), pelvic ganglia (PG) and some dorsal root ganglia (DRG). Immunohistochemistry revealed that the vast majority of CaMG and SChG BG-projecting neurons contained tyrosine hydroxylase (TH) and dopaminebeta-hydroxylase (DbetaH), and some neuropeptides including neuropeptide Y (NPY), somatostatin (SOM) and galanin (GAL). Three subpopulations of PG neurons supplying BG could be distinguished: 1) cholinergic neurons [vesicular acetylcholine transporter (VAChT)-positive] which also contained vasoactive intestinal polypeptide (VIP), nitric oxide synthase (NOS), SOM and NPY, 2) adrenergic neurons (TH-positive) which also stained for NPY, GAL or leu5-enkephalin (LEU), and 3) non-adrenergic, non-cholinergic neurons (NANC). DRG BG-projecting neurons contained mostly substance P (SP) and/or calcitonin gene-related peptide (CGRP) which sometimes colocalized with GAL. The possible functional significance of the substances found within the neurons is discussed.
Pol J Vet Sci 2004
PMID:Immunohistochemical characteristics of neurons supplying the porcine bulbourethral gland. 1523 May 45


<< Previous 1 2 3 4 5 6 7 Next >>